

[World Neurosurg.](#) 2024 Mar 13:S1878-8750(24)00403-0. doi: 10.1016/j.wneu.2024.03.028.

Online ahead of print.

# Genetically Distinct Oligosarcoma Arising from Oligodendroglioma: Systematic Review & Illustrative Case Example

Alexander Evans <sup>1</sup>, Kiana Y Prather <sup>1</sup>, James Battiste <sup>1</sup>, Kar-Ming Fung <sup>2</sup>, Ian F Dunn <sup>1</sup>, Christopher S Graffeo <sup>3</sup>

Affiliations

PMID: 38490447 DOI: [10.1016/j.wneu.2024.03.028](https://doi.org/10.1016/j.wneu.2024.03.028)

## Abstract

**Background:** Oligosarcoma is a rare central nervous system (CNS) neoplasm that may arise following oligodendroglioma resection, which demonstrates a unique genetic profile and aggressive clinical phenotype. We present a systematic review and illustrative case example emphasizing the clinical and prognostic features of this unusual and unfavorable neuro-oncologic disease.

**Methods:** Systematic literature review and illustrative case report.

**Results:** A 41-year-old man who had undergone two neurosurgical resections for a WHO grade II oligodendroglioma (Ki-67=5-10%, 1p/19q co-deleted, IDH2 mutated), without adjuvant chemoradiation, presented with seizures seven years after resection. An extra-axial mass was identified adjacent to the resection cavity, in which gross total resection was achieved. Pathology confirmed WHO grade IV oligosarcoma (Ki-67=20%). Adjuvant chemoradiation was initiated, with disease control observed over 6 months of follow-up. 7 publications met inclusion criteria. Oligosarcoma has been confirmed in 36 lesions, arising in 35 patients; 5 were primary oligosarcoma, while 31 occurred in the setting of prior resected oligodendroglioma or oligoastrocytoma. Features shared by these lesions include re-gain of H3K27me3 expression, 1p/19q codeletion, homozygous deletion of CDKN2A/B, loss of 6q, loss of NF1 and YAP1, and attenuation of CpG island methylator (G-CIMP). Median survival after oligosarcoma diagnosis was 1.3 years (range, 0-5.2; n=35).

**Conclusion:** Oligosarcoma is a prognostically unfavorable CNS neoplasm with characteristic imaging and pathologic features, and a strong association with previously resected oligodendroglioma. Aggressive treatment is recommended, including gross total resection and adjuvant chemoradiation. Further study is required to define optimal treatment protocol for this CNS malignancy.

**Keywords:** genetics; oligodendroglioma; oligosarcoma; recurrence.

Copyright © 2024 Elsevier Inc. All rights reserved.

[PubMed Disclaimer](#)